FDC Ltd. (FDC) AI Stock Analysis

FDC Ltd.

(NSE:FDC)

Select Model

Rating:58Neutral

Price Target:INR 392.00▲(4.08% Upside)

Action:reiterated

Date:08/28/26

The company's fortress-like balance sheet is its primary strength, but this is offset by significant technical weakness and deteriorating cash flow quality. The stock is under heavy selling pressure, trading below all key moving averages with bearish momentum. While the valuation is fair, the combination of operational headwinds and a weak technical backdrop results in a below-average overall score.

Positive Factors

Conservative Balance SheetVery low leverage reduces refinancing risk and preserves financial flexibility for operations, investment, and potential growth initiatives. A strengthening equity base also provides resilience through business cycles, making the company less dependent on external funding over the next several quarters.

Negative Factors

Volatile Free Cash FlowUneven free-cash-flow conversion reduces visibility into internally generated funding and makes financial performance less predictable. Volatility may constrain the timing of investment, shareholder returns, or other capital-allocation decisions even though operating cash flow remains meaningful and free cash flow is positive.

FDC Ltd. (FDC) vs. iShares MSCI India ETF (INDA)

Market Cap: INR 61.38B
Dividend Yield: 1.32%
Average Volume (3M): 13.23K
Price to Earnings (P/E): 19.6
Beta (1Y): 0.85
Revenue Growth: 10.20%
EPS Growth: 38.95%
Country: India
Employees: 7,076
Sector: General
Sector Strength: 55
Industry: Drug Manufacturers - Specialty & Generic

FDC Ltd. Business Overview & Revenue Model

Company Description

FDC Limited, together with its subsidiaries, manufactures and trades in pharmaceutical products in India, the United States, and internationally. The company offers pharmaceutical formulations for various therapeutic segments, including anti-infectiv...

How the Company Makes Money

FDC makes money primarily by selling pharmaceutical and healthcare products. Revenue is generated from (1) sales of prescription medicines supplied to healthcare providers, hospitals, and pharmacies, and (2) sales of other healthcare products sold th...

FDC Ltd. Financial Statement Overview

Summary

The balance sheet is exceptionally strong (Score 92) with negligible debt, providing a solid foundation. However, the income statement (Score 62) shows moderating revenue growth and margin pressure, while cash flows (Score 55) are volatile with weak free cash flow conversion. The overall financial picture is stable but faces operational headwinds.

Income Statement

62Positive

Balance Sheet

92Very Positive

Cash Flow

55Neutral

Financial statement breakdown
Breakdown	TTM	Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022
Income Statement
Total Revenue	22.89B	21.71B	21.08B	19.35B	17.84B	15.26B
Gross Profit	9.74B	9.18B	8.36B	6.51B	11.28B	9.78B
EBITDA	3.79B	4.39B	4.15B	4.40B	3.01B	3.30B
Net Income	3.13B	2.81B	2.67B	3.05B	1.94B	2.16B
Balance Sheet
Total Assets	31.76B	29.19B	27.14B	24.68B	23.43B	22.70B
Cash, Cash Equivalents and Short-Term Investments	6.22B	5.23B	5.37B	4.75B	4.84B	5.39B
Total Debt	128.20M	154.65M	211.68M	205.19M	283.20M	322.04M
Total Liabilities	5.07B	4.34B	4.33B	3.71B	3.62B	3.14B
Stockholders Equity	26.69B	24.85B	22.81B	20.97B	19.82B	19.57B
Cash Flow
Free Cash Flow	0	622.92M	2.67B	1.27B	418.21M	291.08M
Operating Cash Flow	0	2.49B	3.64B	2.21B	1.55B	1.62B
Investing Cash Flow	0	-1.59B	-2.47B	-170.83M	111.35M	-1.45B
Financing Cash Flow	0	-925.39M	-913.47M	-2.02B	-1.80B	-98.37M

FDC Ltd. Technical Analysis

Technical Analysis SentimentPositive

Last Price376.65

Price Trends

50DMA345.96Positive

100DMA373.34Positive

200DMA370.66Positive

Market Momentum

MACD5.93Negative

RSI66.77Neutral

STOCH84.47Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:FDC, the sentiment is Positive. The current price of 376.65 is above the 20-day moving average (MA) of 345.69, above the 50-day MA of 345.96, and above the 200-day MA of 370.66, indicating a bullish trend. The MACD of 5.93 indicates Negative momentum. The RSI at 66.77 is Neutral, neither overbought nor oversold. The STOCH value of 84.47 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:FDC.

FDC Ltd. Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

IN:FDC against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IN:STAR	74Outperform	INR 98.55B	15.97	―	0.47%	11.28%	55.18%
IN:BLISSGVS	69Neutral	INR 68.94B	50.66	―	0.23%	20.59%	27.16%
IN:FDC	58Neutral	INR 61.32B	19.59	―	1.32%	10.20%	38.95%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
IN:ORCHPHARMA	54Neutral	INR 49.89B	489.15	―	―	10.83%	-89.83%
IN:UNICHEMLAB	51Neutral	INR 34.04B	11.17	―	―	9.43%	132.94%
IN:INDOCO	47Neutral	INR 19.23B	61.26	―	0.10%	10.75%	―

* General Sector Average

Performance Comparison

IN:FDC and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
IN:FDC	FDC Ltd.	376.65	-78.95	-17.33%
IN:BLISSGVS	Bliss Gvs Pharma Limited	648.40	494.04	320.05%
IN:INDOCO	Indoco Remedies Limited	208.35	-64.66	-23.68%
IN:ORCHPHARMA	Orchid Pharma Limited	833.05	64.40	8.38%
IN:STAR	Strides Pharma Science Ltd	1069.15	89.49	9.13%
IN:UNICHEMLAB	Unichem Laboratories Limited	483.45	9.00	1.90%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Aug 28, 2026

FDC Ltd. AI Stock Analysis